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Background: The incidence of cardiac events is higher in patients with diabetes than in people without diabetes.
The Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese
Subjects (COSMOS) demonstrated significant plaque regression in Japanese patients with chronic coronary disease
after 76 weeks of rosuvastatin (2.5 mg once daily, up-titrated to a maximum of 20 mg/day to achieve LDL
cholesterol <80 mg/dl).
Methods: In this subanalysis of COSMOS, we examined the association between HbA1c and plaque regression in
40 patients with HbA1c ≥6.5% (high group) and 86 patients with HbA1c <6.5% (low group).
Results: In multivariate analyses, HbA1c and plaque volume at baseline were major determinants of plaque
regression. LDL cholesterol decreased by 37% and 39% in the high and low groups, respectively, while HDL
cholesterol increased by 16% and 22%, respectively. The reduction in plaque volume was significantly (p = 0.04)
greater in the low group (from 71.0 ± 39.9 to 64.7 ± 34.7 mm3) than in the high group (from 74.3 ± 34.2 to
71.4 ± 32.3 mm3). Vessel volume increased in the high group but not in the low group (change from baseline:
+4.2% vs −0.8%, p = 0.02). Change in plaque volume was significantly correlated with baseline HbA1c.
Conclusions: Despite similar improvements in lipid levels, plaque regression was less pronounced in patients with
high HbA1c levels compared with those with low levels. Tight glucose control during statin therapy may enhance
plaque regression in patients with stable coronary disease.
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Intravascular ultrasound (IVUS) has been widely applied
in recent clinical trials focusing on coronary atheroscler-
osis [1–6] and has provided new insights into the patho-
physiology of atherosclerotic plaque progression and
regression.
Plaque regression has been documented in several
studies using IVUS to investigate the effects of lipid-
lowering therapies, as well as those of anti-hypertensive
drugs and anti-diabetic drugs [7–10]. The results of
those studies indicate that plaque regression is influ-
enced by several clinical factors, including lipid profiles,
diabetic status and blood pressure. Interestingly, diabetic
status appears to be one of the major determinants of
plaque progression and/or regression [11]. Moreover,
diabetes mellitus is an important residual risk factor for
prevention of atherosclerotic disease following LDL
cholesterol (LDL-C)-lowering therapy [12].
HbA1c has long been used as a marker for glycaemic
control in patients with diabetes mellitus and in people
with prediabetes [13]. Several epidemiological studies
have shown a positive association between HbA1c and
risk of cardiovascular disease [14,15]. However, it is un-
known whether glucose control is associated with the
change in plaque volume following interventions to treat
dyslipidaemia, for example.
The Coronary Atherosclerosis Study Measuring Effects
of Rosuvastatin Using Intravascular Ultrasound in Japanese
Subjects (COSMOS, ClinicalTrials.gov Identifier: NCT
00329160) was a multicentre, open-label trial con-
ducted in 37 institutions in Japan. The study examined
the effects of rosuvastatin on plaque volume in 214
hypercholesterolaemic patients with stable coronary artery
disease using IVUS [5,6]. In this trial, rosuvastatin
decreased LDL-C and increased HDL cholesterol (HDL-C),
which significantly reduced plaque volume by 5%.
Considering the limited understanding of whether glucose
control is associated with changes in plaque volume, we
conducted a subanalysis of the COSMOS study to analyse
the relationship between HbA1c and change in plaque
volume following 76 weeks of treatment with rosuvastatin.Methods
Study design
The study design and primary outcomes of the COS-
MOS study are reported in more detail elsewhere [5,6].
Briefly, the COSMOS study was a 76-week, open-label,
multicentre study to evaluate the effects of rosuvastatin
on coronary artery atheroma volume, as measured by
IVUS, in patients with stable coronary artery disease. Eli-
gible patients were started on 2.5 mg rosuvastatin once
daily, which was up-titrated to a maximum of 20 mg/day
to achieve a treatment goal of LDL-C <80 mg/dl.Subjects attended follow-up visits every 4 weeks for
76 weeks after commencing treatment with rosuvastatin.
IVUS and coronary angiography (CAG) were performed
at baseline and at week 76. All subjects signed an
informed consent form. This study was approved by in-
stitutional review boards or independent ethics commit-
tees at all participating centres.
Patients
A total of 126 patients completed the COSMOS study and
were included in the study database used for this subana-
lysis. These patients met all of the following inclusion cri-
teria: 20–75 years old; undergoing elective CAG or
percutaneous coronary intervention (PCI); serum LDL-C
≥140 mg/dl or TC ≥220 mg/dl in untreated patients, or
LDL-C ≥100 mg/dl or TC ≥180 mg/dl in patients already
treated with lipid-lowering agents; at least one significant
stenosis of ≥75% as a candidate for PCI; and at least one
untreated non-culprit target lesion with ≤50% stenosis
that could be imaged by IVUS. Exclusion criteria included
the following: acute myocardial infarction within 72 h of
the start of the study; heart failure of New York Heart As-
sociation class III or IV; secondary hyperlipidaemia; treat-
ment with cyclosporine on haemodialysis; left main
coronary artery disease with >50% stenosis; uncontrolled
hypertension (diastolic blood pressure ≥110 mmHg or
systolic blood pressure ≥200 mmHg for all measurements
during the screening period); uncontrolled diabetes
(HbA1c ≥9.5%); active liver disease or liver dysfunction
with ≥2.5× the upper limit of normal (ULN) level for ala-
nine aminotransferase, aspartate aminotransferase or alka-
line phosphatase, or total bilirubin ≥3.0 mg/dl; creatinine
clearance <30 ml/min or serum creatinine >2.0 mg/dl;
and serum creatine kinase >3× the ULN. To ensure the
patient population resembled that of actual clinical prac-
tice, we did not exclude patients who were taking lipid-
lowering drugs at study entry.
IVUS procedure
IVUS was used to examine plaque volume, lumen vol-
ume and vessel volume at baseline and after 76 weeks of
treatment. After administering 100–300 μg of intracor-
onary nitroglycerine, the catheter was advanced into the
target vessel and the transducer was positioned as distal
to the target lesion as possible. The operator had a
motor driving pullback system that progressively with-
drew the transducer at a speed of 0.5 mm/second. A
ClearviewW, Galaxy™ or Galaxy2™ ultrasound system
with the Atlantis™ SR Pro 2 40 MHz imaging catheter
(Boston Scientific, Natick, MA, USA) was used for both
the baseline and follow-up examinations. The images
were optimised visually by manipulating the system set-
tings. IVUS images were recorded on super-VHS video-
tapes or Digital Video Disk plus Re-Writable disks.
Table 1 Univariate analyses for the determinants of
plaque progression
Factor β 95% CI p Value
BMI 0.766 0.017, 1.514 0.045
Use of ACE inhibitors −6.655 −12.604, –0.706 0.0286
Use of sulfonylureas 6.672 0.100, 13.244 0.0467
HbA1c 2.941 0.452, 5.429 0.0209
Evaluated plaque length −0.997 −1.698, –0.296 0.0057
Plaque volume −0.112 −0.174, –0.049 0.0006
Vessel volume −0.047 −0.080, –0.013 0.0067
Plaque area −0.918 −1.598, –0.238 0.0086
BMI, body mass index.
Parameters with p values <0.05 by univariate analysis are listed.
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Plaque volume was assessed by volumetric analysis using
the echoPlaque2 system (Indec Systems Inc., Santa
Clara, CA, USA). Baseline and follow-up IVUS images
were reviewed side-by-side on a display, and the target
segment was selected. The target segment to be moni-
tored was determined in a non-PCI site (>5 mm prox-
imal or distal to the PCI site) with a reproducible feature
such as a side branch and its bifurcation, calcifications,
or stent edges. A series of cross-sectional images taken
every 0.09 mm were measured by manual on-screen
planimetry. IVUS tracing was performed in accordance
with the standards of the American College of Cardi-
ology and the European Society of Cardiology [16]. Man-
ual planimetry was used to trace the leading edges of the
luminal and external elastic membrane (EEM) borders.
The images were logged and analysed by two experi-
enced technicians in a central laboratory who were
blinded to the patient’s profile, imaging date and base-
line/follow-up labels. The accuracy and reproducibility
of this method has been established previously [16].
IVUS measurements
The IVUS parameters analysed in this study were per-
cent change in plaque volume of the target lesion from
baseline to follow-up at week 76, percent changes in
lumen volume and vessel volume; and changes in plaque
area, lumen area and vessel area at the plaque segment
with a maximum baseline plaque area.
Percent change in total atheroma volume (TAV) was
calculated as follows: percent change in TAV= [TAV(fol-
low-up) – TAV(baseline)]/[TAV(baseline) × 100]. TAV
was calculated as the sum of the difference between
EEM and luminal area across all evaluated frame images:
TAV=
P
(EEMCSA – lumenCSA), where CSA= cross-sec-
tion area. All IVUS measurements were performed at a
central laboratory.
Laboratory tests
All laboratory measurements were performed at a central
clinical laboratory (SRL, Inc., Tokyo, Japan). HbA1c (%) is
given as National Glycohemoglobin Standardization Pro-
gram (NGSP) equivalent values (%), which were calculated
using the following formula [17]: HbA1c (%) =HbA1c
(Japan Diabetes Society value; %)+ 0.4%. LDL-C was cal-
culated using Friedewald’s formula [18].
Statistical analysis
We used the original COSMOS study database for this
subanalysis [5]. To identify the factors associated with
the percent change in plaque volume, univariate analysis
was performed with 70 baseline characteristics and la-
boratory profiles. Eight factors were significantly asso-
ciated with the percent change in plaque volume.Multivariate regression analysis was performed using the
variables shown to be significant in univariate analyses
with stepwise model selection using p< 0.05 to retain
variables in the model.
We next divided the subjects into two groups accord-
ing to HbA1c (low, <6.5%; high, ≥6.5%) based on the
American Diabetes Association criteria [19]. Continuous
variables were compared between the two groups using
two-sample t-tests, while comparisons between baseline
and follow-up were made using one-sample t-tests. Cat-
egorical variables were compared between the two
groups using χ2 or Fisher’s exact tests. Finally, the gen-
eral linear model was used to examine the relationship
between change in plaque volume and HbA1c. The two-
sided significance level was set at 5%.
Analyses were performed using SAS software, version
9.1.3 (SAS Institute Inc., Cary, NC, USA). Efficacy data
are reported as means ± SD.
Results
As previously reported, 126 patients completed the 76-
week study and changes in lipid levels and plaque volume
following rosuvastatin treatment were successfully mea-
sured [5]. The mean rosuvastatin dose at follow-up IVUS
was 16.9±5.3 mg/day, and 92/126 patients (72.2%) were on
the maximum rosuvastatin dose (20 mg/day). In these
patients (mean±SD; age 62.6±7.7 years, BMI
25.0± 3.3 kg/m2, 76.2% males, 37.3% had diabetes), the per-
cent changes in LDL-C and HDL-C were −38.6± 16.9%
and +19.8±22.9% (both, p< 0.0001). The percent change
in plaque volume was −5.1±14.1% (p< 0.0001). HbA1c
increased slightly but not significantly from 5.92±0.98% at
baseline to 6.25±1.00% at follow-up (p=0.3205).
Determinants of plaque progression
The results of univariate analyses to identify factors asso-
ciated with change in plaque volume are shown in Table 1.
BMI, HbA1c and the use of sulfonylureas were positively
associated with plaque progression. In contrast, the use of
Table 3 Baseline characteristics of patients stratified






Males 65 (75.58%) 31 (77.50%) 1.0000a
Age (years) 62.5 ± 7.9 62.8 ± 7.4 0.8390b
Body weight (kg) 64.81 ± 10.63 67.65 ± 14.51 0.2176b
BMI (kg/m2) 24.68 ± 2.71 25.67 ± 4.23 0.1186b
Lesion length 11.095± 3.398 10.213 ± 3.548 0.1835b
Lesion location
Proximal 15 (17.44%) 18 (45.00%)
Distal 33 (38.37%) 7 (17.50%)
Other 38 (44.19%) 15 (37.50%)
Target vessel
RCA 35 (40.70%) 16 (40.00%)
LAD 25 (29.07%) 13 (32.50%)
LCX 26 (30.23%) 10 (25.00%)
LMT 0 (0.00%) 1 (2.50%)
LLT before enrolment 62 (72.09%) 30 (75.00%) 0.8308a
Hypertension 65 (75.58%) 31 (77.50%) 1.0000a
Smoking 22 (25.58%) 14 (35.00%) 0.2954a
Diabetes mellitus 9 (10.47%) 38 (95.00%) <0.0001a
Family history of CAD 19 (22.09%) 7 (17.50%) 0.6411a
Concomitant therapy
Ca channel blocker 46 (53.49%) 26 (65.00%) 0.2507a
Nitrate 57 (66.28%) 24 (60.00%) 0.5512a
ACE inhibitor 16 (18.60%) 11 (27.50%) 0.3507a
ARB 39 (45.35%) 17 (42.50%) 0.8481a
β-blocker 22 (25.58%) 7 (17.50%) 0.3697a
Thiazolidinedione 0 (0.00%) 9 (22.50%) <0.0001a
Sulfonylurea 3 (3.49%) 18 (45.00%) <0.0001a
α-glucosidase inhibitor 4 (4.65%) 17 (42.50%) <0.0001a
Insulin 1 (1.16%) 10 (25.00%) <0.0001a
Ticlopidine 83 (96.51%) 38 (95.00%) 0.6522a
Clopidogrel 5 (5.81%) 2 (5.00%) 1.0000a
Aspirin 86 (100.00%) 40 (100.00%) 1.0000a
Data are means ± SD or n (%).
a χ2 or Fisher’s exact test; btwo-sample t-tests.
RCA, right coronary artery; LAD, left anterior descending; LCX, left circumflex;
LMT, left main trunk; LLT, lipid-lowering therapy; CAD, coronary heart disease;
HDL-C, HDL-cholesterol; IVUS, intravascular ultrasound; ARB: angiotensin
receptor blocker.
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negatively associated with plaque progression. The pres-
ence of diabetes mellitus was not significantly associated
with change in plaque volume. Multivariate analysis
(Table 2) revealed that HbA1c and plaque volume at base-
line were independent determinants of the change in
plaque volume.
Characteristics of the high and low HbA1c groups
The 126 patients were divided into those with HbA1c
<6.5% (n = 80; low) and those with HbA1c ≥6.5%
(n = 46; high), with mean HbA1c levels at baseline of
5.35 ± 0.32 and 7.14 ± 0.80%, respectively (p< 0.0001).
The baseline characteristics of the two groups were gen-
erally similar except for the prevalence of diabetes melli-
tus, which was higher in the high HbA1c group than in
the low HbA1c group, as would be expected. As a result,
more patients in the high HbA1c group had received
treatment with oral antidiabetic drugs/insulin. Although
the location of the lesion was significantly different be-
tween the two groups, this factor was not associated
with the change in plaque volume. Other characteristics
were not significantly different between the two groups
(Table 3).
Lipid profiles
LDL-C levels decreased from 140.4 to 81.8 mg/dl (by
39.2%) and from 139.7 to 85.3 mg/dl (by 37.3%) in the
high and low HbA1c groups, respectively (Table 4).
LDL-C levels at baseline and follow-up and the percent
change during the observation period were generally
comparable between the two groups. HDL-C levels
increased in both groups, although the magnitude of in-
crease was slightly, but significantly, greater in patients
with HbA1c <6.5% at baseline. VLDL-C decreased by
4.1% in the low HbA1c group, but increased by 18.1% in
the high HbA1c group.
IVUS parameters
There were no significant differences in the baseline IVUS
parameters (plaque volume, lumen volume and vessel vol-
ume) between the two groups of patients (Table 5). Plaque
volume decreased from 71.0± 39.9 to 64.7± 34.7 mm3 (by
6.8%) in the low HbA1c group (p< 0.0001 vs baseline)
and from 74.3± 34.2 to 71.4± 32.3 mm3 (by 1.3%) in the
high HbA1c group. As a result, the percent change inTable 2 Multivariate analysis for the determinants of
plaque progression
Factor β 95% CI p Value
HbA1c 2.683 0.292, 5.074 0.0282
Plaque volume −0.107 −0.169, –0.046 0.0008
Parameters with p values <0.05 by multivariate analysis on parameters in
Table 1 are listed.plaque volume was significantly greater in the low HbA1c
group than in the high HbA1c group (p= 0.0410). Simi-
larly, vessel volume decreased by 0.8% in the low HbA1c
group but increased in the high HbA1c group (by 4.2%),
resulting in a significant difference between the two
groups in terms of percent change in vessel volume
(p= 0.02). In contrast, the change in lumen volume was
not significantly different between the two groups
(p= 0.08). Changes in percent plaque area and percent
Table 4 Changes in laboratory data in patients stratified according to HbA1c at baseline
HbA1c <6.5% (n= 86) HbA1c ≥6.5% (n= 40)
Baseline Follow-up Actual change % change Baseline Follow-up Actual change % change
TC (mg/dl) 214.6 ± 34.5 157.1 ± 20 −57.6 ± 36.9 −25.3 ± 13.9 211.3 ± 35.4 159.3 ± 31.5 −52 ± 34.9 −23.5 ± 15
TG (mg/dl) 145.6 ± 90.3 121 ± 56.2 −24.6 ± 71.1 −8.9 ± 34.7 152.4 ± 75.9 150.4 ± 76.6* −2.0 ± 76.2 4.0 ± 44.6
HDL-C (mg/dl) 47.9 ± 10.7 57.0 ± 11.6 9.2 ± 9.0 21.5 ± 22.3 45.4 ± 11.1 51.3 ± 11† 6.0 ± 10.2 16.0 ± 24
LDL-C (mg/dl) 140.4 ± 32.3 81.8 ± 15.7 −58.7 ± 33.1 −39.2 ± 16.6 139.7 ± 30.1 85.3 ± 23.9 −54.4 ± 31.2 −37.3 ± 17.7
VLDL-C (mg/dl) 25.4 ± 16.7 19.6 ± 10.4 −5.8 ± 14.2 −4.1 ± 61.8 26.7 ± 16.9 26.5 ± 15† −0.2 ± 16.9 18.1 ± 76.9
non-HDL-C (mg/dl) 166.7 ± 33.9 100 ± 16.9 −66.7 ± 33.5 −38.2 ± 13.9 166 ± 33.1 108± 28.5 −58 ± 33 −33.6 ± 17.0
small dense LDL 0.36 ± 0.04 0.35 ± 0.03 −0.01 ± 0.04 −2.77 ± 10.97 0.36 ± 0.04 0.35 ± 0.03 −0.01 ± 0.05 −2.31 ± 11.48
RLP-C (mg/dl) 5.7 ± 5.6 3.6 ± 1.4 −2.1 ± 5.2 −17.3 ± 38.2 5.7 ± 3.7 4.9 ± 2.9† −0.8 ± 3.9 −4 ± 51.3
LDL-C/HDL-C 3.1 ± 1.0 1.5 ± 0.4 −1.6 ± 0.8 −49.1 ± 14.1 3.2 ± 0.9 1.7 ± 0.5† −1.5 ± 0.9 −44.3 ± 16.8
hs-CRP (ng/ml) 2836 ± 7045 821 ± 1331 −2014± 7111 −16.2 ± 104.7 4494 ± 9277 1172± 1934 −3322± 9158 91.9 ± 489.7
Data are means ± SD.
*p< 0.05 and †p< 0.01 vs patients with HbA1c <6.5%.
HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; VLDL-C, VLDL-cholesterol; hs-CRP, high-sensitive C-reactive protein.
Daida et al. Cardiovascular Diabetology 2012, 11:87 Page 5 of 10
http://www.cardiab.com/content/11/1/87vessel area were significantly greater in the low HbA1c
group than in the high HbA1c group (both, p< 0.05).Correlation between HbA1c and IVUS parameters
There was a weak but statistically significant correl-
ation between baseline HbA1c and change in plaque
volume (r = 0.206, p = 0.02) (Figure 1a). Because the
low HbA1c group contained some patients with dia-
betes but good glycaemic control, we subdivided both
groups of patients according to the presence/absence
of diabetes to further examine the role of glycaemic
control in diabetic patients. Interestingly, the correl-
ation between baseline HbA1c and change in plaque
volume was still apparent in diabetic patients, although
this correlation was not statistically significant
(r = 0.263, p = 0.07, Figure 1b). The same correlation
was not apparent in non-diabetic patients (r = 0.062,
p = 0.58, Figure 1c).Table 5 Changes in IVUS parameters in patients stratified acc
HbA1c <6.5% (n = 86)
Baseline Follow-up Actual change % chang
Volume (mm3)
Plaque 71.0 ± 39.9 64.7 ± 34.7 −6.3 ± 12.3*** −6.8 ± 1
Lumen 80.3 ± 41.9 82.4 ± 39.8 2.1 ± 11.3 5.6 ± 1
Vessel 151.4 ± 75.8 147.1 ± 69 −4.3 ± 18.8* −0.8 ± 1
Area (mm2)
Plaque 8.6 ± 3.7 6.4 ± 3.1 −2.2 ± 2.1*** −24.4 ± 2
Lumen 6.0 ± 2.8 6.9 ± 3.2 1.0 ± 1.6*** 20.2 ± 2
Vessel 14.6 ± 5.7 13.4 ± 5.2 −1.2 ± 2.3*** −7.6 ± 1
Data are means ± SD.
*p< 0.05, **p< 0.01, ***p< 0.0001 vs baseline; †p< 0.05 vs patients with HbA1c <6
IVUS, intravascular ultrasound.Discussion
In this subanalysis of the COSMOS study, we found that
baseline HbA1c was significantly associated with change
in plaque volume. Notably, no significant regression was
observed in patients with high HbA1c at baseline. In
contrast, significant plaque regression was observed in
subjects with low HbA1c at baseline, even in those with
diabetes, although the decreases in LDL-C levels were
similar in both groups. This suggests that glycaemic con-
trol, in addition to LDL-C-lowering, is an important de-
terminant of plaque progression or regression. Prior
observational studies have revealed a positive association
between the presence of diabetes mellitus and the inci-
dence of cardiovascular disease [13,15]. Several recent
trials using IVUS have also indicated that diabetes melli-
tus is a major determinant of plaque progression [11,20].
For example, Hiro et al. investigated the effect of aggres-
sive LDL-C lowering on coronary atherosclerosis in 230
patients with acute coronary syndrome and found thatording to HbA1c at baseline
HbA1c ≥6.5% (n = 40)
e Baseline Follow-up Actual change % change
3.9*** 74.3 ± 34.2 71.4 ± 32.3 −2.9 ± 11.4 −1.3 ± 13.8†
5.3** 73.9 ± 36.2 80 ± 38.7 6.1 ± 15.6* 10.8 ± 15.8**
0.7 148.2 ± 65.2 151.4 ± 64.6 3.2 ± 20.5† 4.2 ± 13.1*†
0.5 9.5 ± 3.1 7.9 ± 2.7† −1.7 ± 1.9*** −16.4 ± 17.9†
9.5 6.2 ± 2.4 7.4 ± 3 1.2 ± 1.6*** 21.8 ± 26.4
4.4 15.7 ± 4.6 15.3 ± 4.5† −0.5 ± 2.2 −2.0 ± 14.6†
.5%.
Figure 1 Associations between HbA1c and plaque volume change. Associations in all patients (a), in patients with diabetes mellitus (b), and
in non-diabetic patients (c).
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was weaker in diabetic patients than in non-diabetic
patients [11]. Interestingly, they also found that percent
change in plaque volume was significantly correlated
with LDL-C in patients with diabetes, but not in non-
diabetic patients. Nicholls et al. performed a pooled ana-
lysis of five IVUS trials involving 2,237 subjects and
compared arterial remodelling, extent of coronary ath-
erosclerosis and disease progression between patients
with diabetes and those without [20]. They found that
diabetic patients exhibited greater percent and total ath-
eroma volumes, with more rapid progression of plaque
volume and inadequate compensatory remodelling. They
also found that percent atheroma volume was more
strongly associated with HbA1c than with fasting glu-
cose, although this difference became non-significant
after adjustment for patient background. Similarly, Berry
et al. observed significant associations between fasting
glucose, HbA1c and the presence of diabetes mellitus,
and the severity or progression of coronary atheroscler-
osis in 426 patients who underwent IVUS [21]. Similar
to these earlier studies, we observed a significant associ-
ation between baseline HbA1c and change in plaque
volume.
The reduced plaque regression in patients with high
HbA1c suggests that hyperglycaemia or diabetes mellitus
may be involved in a unique pathogenic mechanism under-
lying plaque formation in these patients. Indeed, hypergly-
caemia could accelerate the development of atherosclerosis
through enhanced production of advanced glycation end
products, oxidative stress and vascular inflammation, which
may contribute to diabetes-specific atherosclerosis [22,23].
This is supported by the results of histological studies and
imaging studies, which have revealed that several features
are more pronounced in diabetic patients, including more
extensive macrophage infiltration, significantly larger lipid
cores, and more abundant dense-calcium or fibrocalcific
tissue [24,25]. More recently, Parathath et al. demonstratedthat diabetes modified plaque macrophage characteristics
and thus hindered plaque regression [26].
As the relationship between the change in plaque vol-
ume and HbA1c was mainly observed in diabetic
patients, and not in non-diabetic patients, HbA1c seems
to be an important determinant of plaque regression in
diabetic patients. Thus, targeting glycaemic control may
aid plaque regression. Indeed several clinical trials have
demonstrated significant plaque regression using oral
antidiabetic drugs. For example, the Pioglitazone Effect
on Regression of Intravascular Sonographic Coronary
Obstruction Prospective Evaluation (PERISCOPE) trial
compared the effects of treatment with pioglitazone or
glimepiride for 18 months on plaque volume in 543
patients with coronary disease and type 2 diabetes [8].
The investigators found that the least squares mean per-
cent atheroma volume decreased from baseline in
patients treated with pioglitazone but increased in
patients treated with glimepiride (−0.16 vs +0.73%, re-
spectively, p = 0.002). HbA1c levels were 7.4 ± 1.0% in
both groups at baseline, with greater decreases in
patients treated with pioglitazone compared with those
treated with glimepiride (−0.55 vs −0.36%, p = 0.03). Pio-
glitazone, but not glimepiride, was also associated with
improvements in lipid levels, including HDL-C and tri-
glycerides, which likely contributed to plaque regression
in this group. These data suggest that interventions that
improve glycaemic control alone may be insufficient to
prevent increases in atheroma volume. Instead, improve-
ments in multiple factors may be necessary to achieve
clinically meaningful plaque regression. Clearly, further
data from this and other studies are needed to examine
the relative contributions of improved control of glucose
and lipid levels to plaque regression.
HbA1c, which is an established diagnostic marker for
diabetes mellitus [19], has been reported to be a signifi-
cant predictor of cardiovascular events in diabetic patients
[14,15]. In fact, a recent meta-analysis demonstrated that
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cardiovascular events, although longer observation peri-
ods than originally expected may be required to examine
this association [27].
Quevedo et al. reported a high prevalence of vessel
shrinkage in diabetic patients, which was associated with
insulin requirement, HbA1c, apolipoprotein B and
hypertension in their study using serial IVUS [28].
Nicholls et al. reported inadequate compensatory re-
modelling in diabetic patients [20]. However, unlike
these earlier observations, in the present study, the per-
cent change in vessel volume during the follow-up
period indicated positive remodelling in patients with
high HbA1c and negative remodelling in patients with
low HbA1c. Reddy et al. also observed greater positive
remodelling in diabetic patients than in non-diabetic
patients [29]. Meanwhile, Chhatriwalla et al. [30] found
that lower levels of LDL-C and systolic blood pressure
were associated with negative remodelling of the elastic
membrane in patients with established coronary artery
disease. Differences in patient characteristics and IVUS
methodologies may partly explain these differences in
vascular remodelling between these studies. Multifactor-
ial treatment strategies targeting not just LDL-C, but
also other risk factors, including glycaemic control and
blood pressure, may be important to achieve negative re-
modelling, and slow the progression of coronary
atherosclerosis.
We observed a slight increase in HbA1c from 5.92 to
6.25% during the study, although this change was not
significant. Some studies have reported that rosuvastatin
and other statins increase markers of insulin resistance,
such as homeostasis model assessment of insulin resist-
ance (HOMA-IR) and fasting insulin levels [31–33]. It is
possible that rosuvastatin reduces insulin sensitivity,
resulting in a slight deterioration in glycaemic control.
However, this effect of rosuvastatin is not consistent
among studies [34–36]. Therefore, we think a more
likely explanation is that the change in HbA1c reflects
the natural progression of insulin resistance or worsen-
ing glycaemic control in a cohort of patients, in which
37.3% had diabetes at baseline. It must also be noted
that the earlier studies were much shorter (total study
length of 1–3 months) than our study, possibly too short
to reliably attribute the changes in HbA1c to rosuvasta-
tin itself. Unfortunately, as we did not measure fasting
glucose or fasting insulin, we were unable to determine
HOMA-IR as a direct marker for insulin resistance. We
should also consider that, although HbA1c is strongly
associated with fasting and post-prandial plasma glucose,
the use of HbA1c rather than specific glucose para-
meters may mask possible associations between plasma
glucose and both fasting/post-prandial glucose excur-
sions and plaque progression.It is also important to consider that other factors not
assessed here may partly explain some of the observed
associations. For example, in a cohort of Korean indivi-
duals with normal glucose tolerance or type 2 diabetes,
serum levels of the adipokine omentin-1 were independ-
ently associated with arterial stiffness and carotid plaque,
even after adjusting for other cardiovascular risk factors
[37].
In the present study, there were some marked differ-
ences in the changes in lipid levels between the two
groups. For example, VLDL-C decreased by 4.1% in the
low HbA1c group, but increased by 18.1% in the high
HbA1c group. The reason for this difference and its clin-
ical relevance are unclear, because VLDL-C was not
associated with plaque progression in univariate ana-
lyses, and was not included in the multivariate model.
Further studies may be required to understand these
results and their possible implications.
This subanalysis of the COSMOS study was a post-
marketing study designed to investigate the effects of in-
tensive LDL-C lowering with rosuvastatin on coronary
atherosclerosis measured using IVUS and its safety; as
such, the lack of glucose measurements and the small
sample size limit further interpretations of the current
results. It is also possible that other factors not assessed
here, including insulin and adipokine concentrations, in-
sulin resistance, and other markers of glycaemic control
may partly explain the associations observed. Neverthe-
less, the association between HbA1c and change in
plaque volume demonstrates the importance of good
glucose control and the unique atherogenic processes in
diabetes. The results also support a prospective interven-
tional trial to better understand the impact of optimal
glycaemic control on plaque regression.
Conclusions
This subanalysis of the COSMOS study revealed a sig-
nificant association between baseline HbA1c and change
in plaque volume. In patients with high HbA1c, no sig-
nificant plaque regression was observed, whereas
marked plaque regression was observed in patients with
low HbA1c, even in those with diabetes, although the
decreases in LDL-C levels were similar in both groups.
These findings, together with earlier results, suggest that
glycaemic control, along with LDL-C, is an important
determinant of plaque progression and regression in
patients with stable coronary artery disease.
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